GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

Zantac 360 Famotidine may also be used for purposes not listed in this medication guide. Heartburn can feel like a heart attack. chest pain that spreads to your jaw or shoulder. Get emergency ...

If you buy through a BGR link, we may earn an affiliate commission, helping support our expert product labs. When the FDA issued a bulletin alerting everyone to the presence of a possible cancer ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

After protracted legal battling, GSK has agreed to pay up to $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

Boehringer Ingelheim is the exception. It has not announced any major settlements. A drug under the name of Zantac 360, which contains no ranidine, is still being currently sold.

A drug currently sold under the name Zantac 360 uses a different active ingredient and contains no ranitidine.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...